Detailed Narrative
Robust H1 FY25 Financial Performance
Jeena Sikho reported a strong H1 FY25, with revenue from operations growing 36% year-on-year to INR214 crores. This growth was primarily fueled by a 72% surge in hospital services revenue, reaching INR114 crores, while product sales also contributed with a 10% increase to INR100 crores. The company achieved an EBITDA of INR59.28 crores, up 32% YoY, maintaining a healthy 28% margin, and PAT grew 47% YoY to INR46.88 crores, reflecting a 21-23% PAT margin.
Aggressive Bed Capacity Expansion and Improved Occupancy
The company is actively expanding its bed capacity, currently managing 1530 beds, up from 1277 beds by March 31st last year. Occupancy rates have significantly improved to 51% in H1 FY25 from 38% in the previous year. Management targets to reach 2100-2200 beds by the end of FY25, 3000 beds by FY26, and an ambitious 5000 beds within the next 3-5 years, with a long-term vision for 10,000 beds. Average Revenue Per Occupied Bed (ARPOB) also saw an increase to INR8100 per day in H1 FY25, up from INR7900 in FY24.
Strategic Entry into OTC Market with Clinical Trial Products
Jeena Sikho is poised to enter the Over-The-Counter (OTC) medicine market within the next three months, following 6 months of homework and trials that generated INR27 lakhs per month in sales. The company has completed 7 clinical trials for products targeting conditions like blood pressure, diabetes, kidney, and liver issues. They plan to launch approximately 12 products, including 6 clinical trial-backed ones, with an ambitious goal to become a top 2-3 player in the Indian Ayurvedic medicine business within two years.
Advancements in Insurance Coverage and Government Empanelment
Significant progress has been made in securing cashless treatment facilities for Ayurvedic services. Following a government notification for all companies to be cashless by April 1, 2024, Jeena Sikho recently signed an agreement with GIPSA, covering four major government insurance companies. Additionally, 11 private insurance companies have already tied up for cashless services, with 16 more pending. The company also highlighted the Supreme Court's order for state governments to include Ayurveda in the Ayushman Yojana, which is expected to further boost patient footfall and occupancy to 80-90%.
International Expansion and Acquisition Strategy
The company is pursuing international expansion, with setups initiated in Nepal and an agreement expected in Dubai within the month. Plans include opening 6 new setups in Dubai within one year and exploring acquisitions there. Domestically, Jeena Sikho is evaluating 3-4 acquisition opportunities, including two factories and other businesses, with one example being Oregano Life (INR100 crores turnover, INR12-13 crores PAT). The strategy also involves revenue-sharing models with existing hospitals to expand reach without significant capex.
Focus on Process-Driven Treatment and Doctor Workforce
Jeena Sikho emphasizes a process-driven treatment protocol, ensuring consistent quality across all hospitals for conditions like kidney failure, cancer, and liver diseases. The company's doctor workforce has grown to 411 on payroll in H1 FY25, up from 307 at the end of FY24, with 1010 doctors in waiting. Management highlighted the ease of recruiting Ayurvedic doctors (BMS degree holders) due to competitive salaries and ESOP plans, with the first round of ESOPs already distributed to 675 employees.
Financial Guidance and Main Board Listing
For FY25, Jeena Sikho targets a revenue of INR450 crores with a 25% PAT margin. Looking ahead, the company aims for INR650-INR700 crores in revenue by FY26 and INR1000 crores by FY28. PAT margins are projected to improve to 27-30% in FY26. The company also confirmed its intention to list on the main board in FY25, with an application planned for March and listing expected by June, after completing three years on the exchange.